Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (NsPFA) Technology to Be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (NsPFA) Technology to Be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--May 16, 2024-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.
加利福尼亞州海沃德--(美國商業資訊)--2024年5月16日--Pulse Biosciences, Inc.（納斯達克股票代碼：PLSE）是一家利用其新型專有CellFx納秒脈衝場消融術（NSPFA）技術的公司，今天宣佈，CellFx nspfa技術將在即將於5月16日至19日在馬薩諸塞州波士頓舉行的2024年心律協會（HRS）年會的多場演講中亮相。
"We look forward to our proprietary CellFX nsPFA technology being highlighted in six total presentations and abstracts, and in a live case presentation at the prestigious HRS meeting," said Darrin Uecker, Chief Technology Officer and Director of Pulse Biosciences. "The preclinical and initial clinical outcomes from studies with our surgical clamp and catheter are encouraging and we continue to believe that CellFX nsPFA can meaningfully advance the treatment of atrial fibrillation."
Pulse Biosciences首席技術官兼董事達林·烏克爾表示：“我們期待在總共六份演示和摘要以及久負盛名的HRS會議的現場案例演示中重點介紹我們專有的CellFx nspfa技術。”“使用我們的手術夾和導管進行研究的臨床前和初步臨床結果令人鼓舞，我們仍然相信CellFx nspFA可以有意義地推進心房顫動的治療。”
"Our innovative energy delivery platform technology allows us to uniquely meet the needs of both cardiac surgeons and EPs who together treat all types of patients with cardiac ailments," added President and Chief Executive Officer Burke T. Barrett. "I am looking forward to speaking with, now as part of Pulse Biosciences, the many providers in the clinical community I have met over the years."
總裁兼首席執行官伯克·巴雷特補充說：“我們創新的能量輸送平台技術使我們能夠獨特地滿足心臟外科醫生和EP的需求，他們共同治療所有類型的心臟病患者。”“作爲Pulse Biosciences的一部分，我期待着與我多年來在臨床界見過的許多提供者交談。”
CellFX nsPFA technology will be featured at the following times at the HRS 2024 Annual Meeting:
CellFx nspfa 技術將在以下時間在 HRS 2024 年年會上亮相：
| Thursday, May 16, 2024 | |
| PFA Live Case Summit | |
| Time: | 1:30pm to 3:00pm ET |
| Location: | Boston Convention & Exhibition Center, Room 210BC |
| Session III - Live/Recorded PFA Cases | |
| Live Case: PVI+ with Nanosecond PFA (CellFX nsPFA; Pulse Biosciences) | |
| Live Case Site: Na Homolce Hospital | |
| Live Case Operators: Jan Petru, MD, and Moritoshi Funasako, MD, PhD | |
| Friday, May 17, 2024 | |
| Presentation | Understanding Novel Ablation Technologies: Insights from Biophysics and Preclinical Studies | |
| Time: | 1:25pm to 1:30pm ET |
| Location: | Moderated Poster Hub 3 - BCEC |
| Nanosecond Pulsed Field Myocardial Ablation: Preclinical Evaluation using a Novel Catheter and Generator (MP-483493-002) | |
| Keita Watanabe, MD (presenting author), Moritz Nies, MD, Abhishek Mann, William Whang, MD, Srinivas R. Dukkipati, MD, Vivek Y. Reddy, MD, Jacob S. Koruth, MD | |
| Saturday, May 18, 2024 | |
| Presentation | Poster Session V - Ablation | |
| Time: | 1:30pm – 3:30pm ET |
| Location: | Abstract Pavilion - BCEC |
| First-in-Human Clinical Experience of Pulse Field Ablation Using Nanosecond Pulses to Treat Atrial Fibrillation (PO-05-158) | |
| Vivek Y. Reddy, MD (presenting author), Jacob S. Koruth, MD, Jan Petru, MD, Moritoshi Funasako, MD, PhD, Pavel Hala, MD, Jan Skoda, MD, Petr Neuzil, MD, PhD | |
| Sunday, May 19, 2024 | |
| Presentation | Poster Session VI - Ablation | |
| Time: | 9:30am to 11:30am ET |
| Location: | Abstract Pavilion - BCEC |
| Focal Nanosecond Pulsed Field Ablation: Preclinical Assessment of a Novel Catheter Tip Design (PO-06-142) | |
| Keita Watanabe, MD (presenting author), Moritz Nies, MD, Srinivas R. Dukkipati, MD, Marc A. Miller, MD, William Whang, MD, Joshua Lampert, MD, Vivek Y. Reddy, MD, Jacob S. Koruth, MD | |
| Exploring Esophageal Effects After Pulsed Field Ablation: Preclinical Evaluation of Nanosecond Pulse using a Dedicated Endocardial System (PO-06-151) | |
| Jacob S. Koruth, MD (presenting author), Moritz Nies, MD, Keita Watanabe, MD, Daniel Musikantow, Mohit Turagam, Joshua Lampert, MD, Marc A. Miller, MD, Vivek Y. Reddy, MD | |
| Performance of the First Bipolar Nanosecond Pulsed Field Ablation (nsPFA) Clamp in a Chronic Porcine Model (PO-06-152) | |
| Gansevoort Hurlbut Dunnington, MD (presenting author), Swami Gnanashanmugam, David Danitz, MSME, Lauren Johnston, Darrin Uecker, MSEE, Jeffrey Litt, Anita Crompton, Mike Smith, Ilya Getsin, Niv Ad, MD | |
| Ultrafast Delivery of Consistent Endocardial and Epicardial Transmural Ablation Lesions Using a New Nanosecond Pulsed Field Ablation (nsPFA) Platform (PO-06-153) | |
| Gansevoort Hurlbut Dunnington, MD (presenting author), Chad Brodt, Swami Gnanashanmugam, David Danitz, MSME, Lauren Johnston, Darrin Uecker, MSEE, Jeffrey Litt, Anita Crompton, Roman Turovskiy, Ilya Getsin, Niv Ad, MD | |
| 2024 年 5 月 16 日，星期四 | |
| PFA 現場案例峯會 | |
| 時間： | 美國東部時間下午 1:30 至下午 3:00 |
| 地點： | 波士頓會展中心，210BC 會議室 |
| 第三節-現場/錄製的 PFA 案例 | |
| 實況案例：採用納秒 PFA 的 PVI+（CellFx nSPFA；Pulse Biosciences） | |
| 現場案例網站：Na Homolce 醫院 | |
| 現場案例操作員：醫學博士 Jan Petru 和醫學博士 Moritoshi Funasako | |
| 2024年5月17日，星期五 | |
| 演講 | 了解新型消融技術：來自生物物理學和臨床前研究的見解 | |
| 時間： | 美國東部時間下午 1:25 至下午 1:30 |
| 地點： | 主持人海報中心 3-BCEC |
| 納秒脈衝場心肌消融術：使用新型導管和發生器進行臨床前評估 (MP-483493-002) | |
| 渡邊啓太，醫學博士 （主講作者），醫學博士 Moritz Nies、Abhishek Mann、醫學博士 William Whang、醫學博士 Srinivas R. Dukkipati、醫學博士 Vivek Y. Reddy、醫學博士 Jacob S. Koruth，醫學博士 | |
| 2024年5月18日，星期六 | |
| 演講 | 海報會議 V-消融 | |
| 時間： | 美國東部時間下午 1:30 — 下午 3:30 |
| 地點： | 抽象館-BCEC |
| 人類首次使用納秒脈衝進行脈衝場消融治療心房顫動的臨床經驗 (PO-05-158) | |
| Vivek Y. Reddy，醫學博士（主講作者）、Jacob S. Koruth，醫學博士、Jan Petru，醫學博士，Moritoshi Funasako，博士，博士，Pavel Hala，醫學博士，Jan Skoda，醫學博士，Petr Neuzil，醫學博士 | |
| 2024 年 5 月 19 日，星期日 | |
| 演講 | 海報會議六-消融 | |
| 時間： | 美國東部時間上午 9:30 至上午 11:30 |
| 地點： | 抽象館-BCEC |
| 焦點納秒脈衝場消融：新型導管尖端設計的臨床前評估 (PO-06-142) | |
| 渡邊凱塔，醫學博士（主持作者），莫里茨·尼斯，醫學博士，斯里尼瓦斯·杜基帕蒂，醫學博士，馬克·米勒，醫學博士，威廉·旺，醫學博士，約書亞·蘭珀特，醫學博士，維維克·雷迪，醫學博士，雅各布·科魯斯 | |
| 探索脈衝場消融後的食道效應：使用專用的心內膜系統對納秒脈衝進行臨床前評估 (PO-06-151) | |
| 醫學博士雅各布·科魯斯（主持作者）、醫學博士莫里茨·尼斯、醫學博士渡邊凱塔、醫學博士丹尼爾·穆西坎託、莫希特·圖拉加姆、醫學博士約書亞·蘭珀特、醫學博士馬克·米勒、醫學博士 Vivek Y. Reddy，醫學博士 | |
| 慢性豬模型中第一個雙極納秒脈衝場消融 (NSPfa) 鉗的性能 (PO-06-152) | |
| Gansevoort Hurlbut Dunnington，醫學博士（主持作者）、斯瓦米·格納納什穆加姆、大衛·丹尼茲、MSME、勞倫·約翰斯頓、達林·尤克、MSEE、傑弗裏·利特、安妮塔·克朗普頓、邁克·史密斯、伊利亞·蓋辛、尼夫·阿德、醫學博士 | |
| 使用新的納秒脈衝場消融術 (NSPfa) 平台超快地提供持續的心內膜和心外膜經壁消融病變 (PO-06-153) | |
| Gansevoort Hurlbut Dunnington，醫學博士（主持作者）、查德·布羅特、斯瓦米·格納納什穆加姆、大衛·丹尼茲、MSME、勞倫·約翰斯頓、達林·尤克、MSEE、傑弗裏·利特、安妮塔·克朗普頓、羅曼·圖羅夫斯基、伊利亞·蓋辛、尼夫·阿德、醫學博士 | |
About Pulse Biosciences
關於脈衝生物科學
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company's proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.
Pulse Biosciences是一家致力於健康創新的新型生物電醫學公司，有可能改善患者的生活質量。該公司專有的CellFx nspfa技術向非熱清除細胞提供納秒脈衝的電能，同時保護鄰近的非細胞組織。該公司正在積極開發其CellFx nspfa技術，該技術用於治療心房顫動以及其他一些市場，在這些市場中，該技術可能會對患者和醫療服務提供者的醫療保健產生深遠的積極影響。
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
Pulse Biosciences、CellFx、Nano-Pulse 刺激、NPS、Nspfa、CellFx Nspfa 和程式化徽標是脈衝生物科學公司在美國和其他國家的商標和/或註冊商標之一。
Forward-Looking Statements
前瞻性陳述
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the potential effectiveness and uniqueness of the Company's CellFX nsPFA technology to treat cardiac ailments, statements concerning pre-clinical or early clinical successes and whether they are predictive of the safety and efficacy of any medical device, and the Company's expectations, whether stated or implied, regarding whether the Company's CellFX nsPFA technology will become a disruptive and durable treatment option for treating any medical condition, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences' current expectations, estimates, and projections regarding Pulse Biosciences' business, operations and other similar or related factors. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expects," "intends," "plans," "projects," "believes," "estimates," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences' control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences' filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
本新聞稿中所有非歷史陳述均爲前瞻性陳述，除其他外，包括與公司CellFx nspfa技術治療心臟疾病的潛在有效性和獨特性有關的陳述，有關臨床前或早期臨床成功的陳述，以及它們是否可以預測任何醫療器械的安全性和有效性的陳述，以及公司對公司的CellFx nspfa技術是否會成爲顛覆性的預期，無論是明示還是暗示的，以及耐久的治療治療任何疾病和其他未來事件的選項。這些陳述不是歷史事實，而是基於Pulse Biosciences當前對Pulse Biosciences業務、運營和其他類似或相關因素的預期、估計和預測。諸如 “可能”、“將”、“可能”、“應該”、“預期”、“預測”、“潛在”、“繼續”、“期望”、“打算”、“計劃”、“項目”、“相信”、“估計” 等詞語以及其他類似或相關的表述用於識別這些前瞻性陳述，儘管並非所有前瞻性陳述都包含這些詞語。您不應過分依賴前瞻性陳述，因爲前瞻性陳述涉及已知和未知的風險、不確定性以及難以或不可能預測的假設，在某些情況下超出了Pulse Biosciences的控制範圍。由於多種因素，包括Pulse Biosciences向美國證券交易委員會提交的文件中描述的因素，實際業績可能與前瞻性陳述中的結果存在重大差異。即使有新信息可用，Pulse Biosciences也沒有義務修改或更新本新聞稿中的信息以反映未來的事件或情況。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240516957050/en/
Investor Contacts:
Pulse Biosciences, Inc.
Burke T. Barrett, President and CEO
IR@pulsebiosciences.com
投資者聯繫人：
Pulse Biosciences
伯克·巴雷特，總裁兼首席執行官
IR@pulsebiosciences.com
Or
或者
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
吉爾馬丁集團
菲利普·泰勒
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
資料來源：Pulse 生物科學公司
譯文內容由第三人軟體翻譯。